PipelineReview.com. Biopharmaceutical News & Clinical Trials
PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
Zydus launches Ujvira (Trastuzumab Emtansine), a ... - Pipelinereview
May 24, 2021 — Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Vaxxinity Announces First Subjects Dosed in Phase 1
Mar 21, 2023 — CAPE CANAVERAL, FL, USA I March 20, 2023 I Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first subjects have been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical trial of VXX-401, an investigational vaccine designed to lower low-density lipoprotein (LDL) cholesterol, a ...
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug …
Jan 9, 2024 — Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Zydus Lifesciences initiates Phase II clinical trial of ZYIL1, a novel ...
Oct 25, 2023 — The Phase 2 clinical trial will assess the safety and efficacy of ZYIL1 in Amyotrophic Lateral Sclerosis (ALS) patients [ClinicalTrials.gov ID: NCT05981040]
Boehringer Ingelheim Begins Clinical Development of First-In-Class ...
May 10, 2023 — INGELHEIM, Germany & SINGAPORE I May 09, 2023 I Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study (NCT05658107) to assess the safety, tolerability, and pharmacokinetics in healthy volunteers.Boehringer Ingelheim is already a global leader in the treatment of pulmonary fibrosis, and the ...
Zydus receives Phase I clinical trial permission for ZYBK2 from DCGI
AHMEDABAD, India I March 03, 2020 I Zydus Cadila, an innovation-driven, global pharmaceutical company, announced that it has received an approval from the Drug Controller General of India (DCGI) to initiate Phase I clinical trials for its Investigational New Drug (IND) ZYBK2, a New Chemical Entity (NCE) intended to treat Rheumatoid Arthritis (RA).. RA is a …
Vaxcyte Announces FDA Clearance of Investigational New
Oct 20, 2023 — Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Biosion Announces Phase II Study Start for Anti-TSLP mAb BSI …
Aug 1, 2023 — NEWARK, NJ, USA and NANJING, China I July 31, 2023 I Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced the phase 2 study initiation for the evaluation of BSI-045B, an anti-TLSP mAb, in the treatment of atopic dermatitis (AD) . “We are pleased to have initiated this important Phase 2 trial, which brings us closer to delivering a new treatment ...
CureVac Announces Positive Phase 2 Interim Data from COVID-19 …
Jan 8, 2024 — Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …